XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.20.2

Per Share Amounts | 6 Months Ended
--- | ---
Jun. 30, 2020
Earnings Per Share [Abstract] |
Per Share Amounts | Per Share Amounts Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. The computation for the three and six-month periods ended June 30, 2020 excluded approximately 420,000 and 410,000, respectively, of the Company’s stock options because the exercise price of the options was higher than the average market price during those periods. The computation for the three and six-month periods ended June 30, 2019 excluded approximately 181,000 and 513,000 respectively, of the Company's stock options because the exercise price of the options was higher than the average market price during those periods. During the three-month period ended June 30, 2020, the Company appointed an Interim President and Chief Executive Officer (“Interim CEO”). As part of his Offer Letter, the Interim CEO was granted 50,000 restricted stock awards that vest in full upon the earlier of August 3, 2020 and the appointment of his successor. In the event the Interim CEO continues to serve the Company after August 3, 2020, he will be granted additional restricted stock awards totaling 10,000 common shares, which will vest in full at the end of each 30-day period after August 3, 2020. The unvested restricted stock awards are included in the denominator for diluted earnings per share for the three and six-month periods ended June 30, 2020. On March 31, 2020, the Company’s Award Agreements (as defined below) expired and the unvested performance share awards were returned to the Company’s stock incentive plan - see Note 7 for further discussion. Based on the guidance provided in accordance with ASC 260 Earnings Per Share (“ASC 260”), the weighted average common shares for basic earnings per share, for the three and six-month periods ended June 30, 2019, excluded the weighted average impact of the unvested performance share awards. These awards were legally outstanding but not deemed participating securities and therefore were excluded from the calculation of basic earnings per share. The unvested shares were also excluded from the denominator for diluted earnings per share because they were considered contingent shares not deemed probable as of June 30, 2019. The following table sets forth the computation of basic and diluted earnings per share for the three and six-month periods ended June 30, 2020 and 2019:
|  | Three Months ended June 30, |  |  |  | Six Months ended June 30, |  |
|  | 2020 |  | 2019 |  | 2020 |  | 2019
Net (loss) income attributable to American Shared Hospital Services |  | $ | (483,000) |  |  | $ | 31,000 |  |  | $ | (618,000) |  |  | $ | 301,000 |
Weighted average common shares for basic earnings per share |  | 6,008,000 |  |  | 5,876,000 |  |  | 6,066,000 |  |  | 5,862,000 |
Diluted effect of stock options and restricted stock awards |  | 69,000 |  |  | 30,000 |  |  | 69,000 |  |  | 33,000 |
Weighted average common shares for diluted earnings per share |  | 6,077,000 |  |  | 5,906,000 |  |  | 6,135,000 |  |  | 5,895,000 |
Basic (loss) earnings per share |  | $ | (0.08) |  |  | $ | 0.01 |  |  | $ | (0.10) |  |  | $ | 0.05 |
Diluted (loss) earnings per share |  | $ | (0.08) |  |  | $ | 0.01 |  |  | $ | (0.10) |  |  | $ | 0.05 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration